SUN-358 Dual Release Hydrocortisone as a New Treatment for Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency

In patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency, long-acting glucocorticoids (GCs) and/or multiple daily dose short-acting GCs are historically suggested to disease management. However, these treatment strategies are generally associated with GC overexposure, w...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Endocr Soc
Autors principals: Simeoli, Chiara, Ferrigno, Rosario, Angellotti, Domenico, Iacuaniello, Davide, Pivonello, Claudia, Negri, Mariarosaria, Di Gennaro, Gilda, De Martino, Maria Cristina, Colao, Annamaria, Pivonello, Rosario
Format: Artigo
Idioma:Inglês
Publicat: Endocrine Society 2019
Matèries:
Adrenal
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6552856/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-358
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars